| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
11 analysts have shared their evaluations of Natera (NASDAQ:NTRA) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 2 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $111.91, a high estimate of $137.00, and a low estimate of $85.00. Witnessing a positive shift, the current average has risen by 23.28% from the previous average price target of $90.78.
The standing of Natera among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mark Massaro | BTIG | Raises | Buy | $125.00 | $100.00 |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $130.00 | $100.00 |
| Dan Brennan | TD Cowen | Raises | Buy | $137.00 | $123.00 |
| Catherine Ramsey | Baird | Raises | Outperform | $117.00 | $99.00 |
| Matthew Sykes | Goldman Sachs | Raises | Buy | $100.00 | $90.00 |
| Alexander Nowak | Craig-Hallum | Announces | Buy | $117.00 | - |
| Eve Burstein | Bernstein | Announces | Outperform | $120.00 | - |
| David Westenberg | Piper Sandler | Raises | Overweight | $110.00 | $70.00 |
| Matthew Sykes | Goldman Sachs | Raises | Buy | $90.00 | $80.00 |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $100.00 | $87.00 |
| Andrew Cooper | Raymond James | Raises | Outperform | $85.00 | $68.00 |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Natera's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Natera analyst ratings.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Natera's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.2% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Natera's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -18.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Natera's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -8.67%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Natera's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.65%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.54.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: NTRA
